CoChat

PCSK9 rs11591147 R46L loss‐of‐function variant protects against liver damage in individuals with NAFLD

Open access
Grimaudo, Stefania, Bartesaghi, Stefano, Rametta, Raffaela, Marra, Fabio, Margherita Mancina, Rosellina, Pihlajamäki, Jussi, Kakol‐Palm, Dorota, Andréasson, Anne‐Christine, Dongiovanni, Paola, Ludovica Fracanzani, Anna, Lori, Giulia, Männistö, Ville, Pellegrini, Giovanni, Bohlooly‐Y, Mohammad, Pennisi, Grazia, Maria Pipitone, Rosaria, Spagnuolo, Rocco, Craxì, Antonio, Lindén, Daniel, Valenti, Luca, Romeo, Stefano, Petta, Salvatore · 2021 · Liver International
Cited by 54

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Background and Aims: The proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a key role in cholesterol homeostasis, and its inhibition represents an effective therapy to lower low‐density lipoprotein cholesterol (LDL‐C) levels. In this study, we examined the impact of the PCSK9 rs11591147 loss‐of‐function (LOF) variant on liver damage in a multicenter collection of patients at risk of nonalcoholic steatohepatitis (NASH), in clinical samples and experimental models. Methods: We considered 1874 consecutive individuals at risk of NASH as determined by histology. The SNP rs11591147, encoding for the p.R46L variant of PCSK9, was genotyped by TaqMan assays. We also evaluated 1) PCSK9 mRNA hepatic expression in human liver, and 2) the impact of a NASH‐inducing diet in mice with hepatic overexpression of human PCSK9. Results: Carriers of PCSK9 rs11591147 had lower circulating LDL‐C levels and were protected against nonalcoholic fatty liver disease (NAFLD) (OR: 0.42; 95% CI: 0.22‐0.81; P = .01), NASH (OR: 0.48; 95% CI: 0.26‐0.87; P = .01) and more severe fibrosis (OR: 0.55; 95% CI: 0.32‐0.94; P = .03) independently of clinical, metabolic and genetic confounding factors. PCSK9 hepatic expression was directly correlated with liver steatosis (P = .03). Finally, liver‐specific overexpression of human PCSK9 in male mice drives NAFLD and fibrosis upon a dietary challenge. Conclusions: In individuals at risk of NASH, PCSK9 was induced with hepatic fat accumulation and PCSK9 rs11591147 LOF variant was protective against liver steatosis, NASH and fibrosis, suggesting that PCSK9 inhibition may be a new therapeutic strategy to treat NASH.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/liv.14711

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 54

Metadata

Authors
Grimaudo, S., Bartesaghi, S., Rametta, R., Marra, F., Margherita Mancina, R., Pihlajamäki, J., Kakol‐Palm, D., Andréasson, A., Dongiovanni, P., Ludovica Fracanzani, A., Lori, G., Männistö, V., Pellegrini, G., Bohlooly‐Y, M., Pennisi, G., Maria Pipitone, R., Spagnuolo, R., Craxì, A., Lindén, D., Valenti, L., Romeo, S., & Petta, S.
Venue
Liver International
Publisher
Wiley
Published
2020-11-02
Volume
41
Issue
2
Pages
321-332
ISSN
  • 0106-9543 (ISSN-L)
  • 1478-3223
  • 1478-3231
OpenAlex
W3093632264
Cited by
54
References
15
FWCI
3.69
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.